mito-met10

**Mito-met10** is a **mitochondria-targeted analog of metformin** created by attaching metformin to a triphenylphosphonium cation (TPP⁺) via a 10-carbon aliphatic chain[1][2][3][4]. This modification dramatically increases mitochondrial uptake and enhances antitumor activity, making mito-met10 up to 1,000 times more effective than metformin in inhibiting pancreatic ductal adenocarcinoma (PDAC) proliferation, both in vitro and in preclinical mouse models, with substantially lower required concentrations[1][3][4]. It acts primarily as a **potent inhibitor of mitochondrial complex I**, causing elevated generation of mitochondrial reactive oxygen species (superoxide and H₂O₂), increased AMPK activation, reduction of ATP levels, and significant G1 cell cycle arrest in cancer cells[1][2][4]. The compound also demonstrates increased tumor radiosensitization and alleviates tumor hypoxia by decreasing oxygen consumption rates in tumors[1][2][3][4]. Notably, its antiproliferative and radiosensitizing effects appear highly selective for cancer cells, with minimal impact on non-transformed cells and low off-target toxicity in animal models[1][4]. Originally described by academic researchers for cancer applications, mitochondrial targeting enhances its efficacy, enabling potential clinical translation for aggressive solid tumors like pancreatic and prostate cancers[1][2][3][4].

Other names

mito-met10mito-met-10mito-met 10mito-metformin 10mito-metformin10mito-metformin-10MM10MM-10MM 10